Exendin-4 Improves Steatohepatitis by Increasing Sirt1 Expression in High-Fat Diet-Induced Obese C57BL/6J Mice
Open Access
- 17 February 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (2), e31394
- https://doi.org/10.1371/journal.pone.0031394
Abstract
The effects of exendin-4 on Sirt1 expression as a mechanism of reducing fatty liver have not been previously reported. Therefore, we investigated whether the beneficial effects of exendin-4 treatment on fatty liver are mediated via Sirt1 in high-fat (HF) diet-induced obese C57BL/6J mice and related cell culture models. Exendin-4 treatment decreased body weight, serum free fatty acid (FA), and triglyceride levels in HF-induced obese C57BL/6J mice. Histological analysis showed that exendin-4 reversed HF-induced hepatic accumulation of lipids and inflammation. Exendin-4 treatment increased mRNA and protein expression of Sirt1 and its downstream factor, AMPK, in vivo and also induced genes associated with FA oxidation and glucose metabolism. In addition, a significant increase in the hepatic expression of Lkb1 and Nampt mRNA was observed in exendin-4-treated groups. We also observed increased expression of phospho-Foxo1 and GLUT2, which are involved in hepatic glucose metabolism. In HepG2 and Huh7 cells, mRNA and protein expressions of GLP-1R were increased by exendin-4 treatment in a dose-dependent manner. Exendin-4 enhanced protein expression of Sirt1 and phospho-AMPKα in HepG2 cells treated with 0.4 mM palmitic acid. We also found that Sirt1 was an upstream regulator of AMPK in hepatocytes. A novel finding of this study was the observation that expression of GLP-1R is proportional to exendin-4 concentration and exendin-4 could attenuate fatty liver through activation of Sirt1.Keywords
This publication has 34 references indexed in Scilit:
- Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathwayHepatology, 2010
- PGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditureCurrent Opinion in Lipidology, 2009
- AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activityNature, 2009
- Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathwayBiochemical and Biophysical Research Communications, 2009
- Resveratrol alleviates alcoholic fatty liver in miceAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2008
- SIRT1 Modulation of the Acetylation Status, Cytosolic Localization, and Activity of LKB1Journal of Biological Chemistry, 2008
- SirT1 Gain of Function Increases Energy Efficiency and Prevents Diabetes in MiceCell Metabolism, 2008
- SIRT1 Regulates Hepatocyte Lipid Metabolism through Activating AMP-activated Protein KinaseJournal of Biological Chemistry, 2008
- Treatment of non-alcoholic fatty liver diseasePostgraduate Medical Journal, 2006
- Design and validation of a histological scoring system for nonalcoholic fatty liver diseaseHepatology, 2005